

Anti-BDCA-2 Antibody (Litifilimab Biosimilar)

Cat. No. AB470


Description	
Reactivities	Human/Cynomolgus
Target	BDCA-2
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	51.68 kDa and 23.76 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 μ M filtered
Endotoxin	Less than 1 EU per μ g by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)- α/β -controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potentially inhibits secretion of IFN- α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.	

Assay Data

Bis-Tris PAGE



Litifilimab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


SEC-HPLC

Anti-BDCA-2 Antibody (Litifilimab Biosimilar)

Cat. No. AB470



Assay Data




The purity of Litifilimab Biosimilar is greater than 95% as determined by SEC-HPLC.

Assay Data

ELISA Data

Litifilimab Biosimilar ELISA

0.05µg Human BDCA-2, His Tag Per Well



Immobilized Human BDCA-2, His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Litifilimab Biosimilar with the EC50 of 3.4ng/ml determined by ELISA.